What's Happening?
Pfizer's antibody-drug conjugate, sigvotatug vedotin, failed to demonstrate an improvement in overall survival in a Phase 3 trial for metastatic non-squamous non-small cell lung cancer (NSCLC). The trial, SigVie-002, compared the drug to the chemotherapy
docetaxel and involved patients who had undergone one or more prior treatments. Despite the setback, Pfizer reported encouraging trends in a subgroup of patients treated with only one prior therapy, showing improved overall survival and progression-free survival. The drug targets integrin beta-6, a protein overexpressed in tumor cells but not in healthy lung tissues.
Why It's Important?
This development is significant for Pfizer, which had positioned sigvotatug vedotin as a key asset in its cancer treatment portfolio following its acquisition of Seagen. The failure to meet the primary endpoint in this trial underscores the challenges in developing new therapies for NSCLC, a major cause of cancer mortality. The results may influence Pfizer's strategic focus on earlier treatment settings and combination therapies, potentially affecting its long-term growth and innovation goals in oncology.
What's Next?
Pfizer plans to shift its focus to testing sigvotatug vedotin as a first-line therapy in combination with Keytruda, a PD-1 inhibitor, in ongoing trials. The company is also exploring other combinations, including with a novel bispecific antibody targeting PD-1 and VEGF. These efforts aim to leverage the drug's potential to induce immunogenic cell death and improve treatment outcomes in earlier stages of cancer. Additionally, Pfizer is developing new generations of ADCs with different payloads to enhance efficacy.
